The first percutaneous injection of bone cement into the spine was performed in 1984 by Dr. H. Deramond (Amiens, France) to treat a 54 year old woman with extreme pain caused by a haemangioma in the second cervical vertebra. Surprisingly, pain relief was complete. After the case was published, indications for percutaneous vertebroplasty quickly expanded to include treatment of chronic back pain caused by metastases and osteoporotic fracture.
The first percutaneous injection of bone cement into the spine was performed in 1984 by Dr. H. Deramond (Amiens, France) to treat a 54 year old woman with extreme pain caused by a haemangioma in the second cervical vertebra. Surprisingly, pain relief was complete. After the case was published, indications for percutaneous vertebroplasty quickly expanded to include treatment of chronic back pain caused by metastases and osteoporotic fracture.
Since then, many case series (Without randomization) have indicated that vertebroplasty is an effective way to control the pain of vertebral compression fracture caused by osteoporosis (figure 1).
Educational Objectives in this presentation: • To show the new randomized double blind multicentre studies • Discuss the utility of vertebroplasty to treat osteoporosis • Identify ideal candidates for Vertebroplasty • Discuss the future of vertebroplasty • In our department we tried since the beginning (1995) of the Vertebroplasty procedure in our hospital to start with a double blind multicentre randomized study. VERTOS I. 1 In this study 34 patients were randomized (18 Vertebroplasty-16 CT (conservative therapy)) recent osteoporotic fracture 6w-6m. with bone marrow oedema on Mirth patients improvement in the vertebroplasty group was fairly consistent so that all the patient of the other group went in crossover after 2 weeks (14/16 from CT to V ).The follow up was 2 weeks and the VAS pain score 8,2 +/-1,21 → 2,1 +/-1,91(1week) • This small randomized trial showed that vertebroplasty reduced disability and improved quality of life at 2 weeks compared with non-surgical treatment, but the crossovers preclude long-term comparisons. 
Procedure
• We reviewed the entire patient population with osteoporosis from 1995 until the end of 2008. Our studynurse interrogated all patients with back-pain and positive bone marrow oedema on MRI. Because she was responsible for all the osteoporotic patients in our hospital she had also access to the data of other departments such as orthopaedics and pneumology. Patients were excluded if they were younger than 50 years of age ;had chronic fractures, canal narrowing, had allergy to vertebroplasty materials or contraindications to MRI. Or if their vertebral fractures were from primary bone tumours, osteoblastic metastasis, or they used anticoagulation therapy. • The vertebroplasties were done with a standardised needle and unique cement (polymethylmethacrylate bone cement manufactured by Cook company Bloomington USA). Percutaneous approach is done uni-or bipedicular under deep sedation with local anaesthesia or general anaesthesia (3%). • All patient received analgesics,3 hour bed rest, bracing, and physiotherapy and walking aid if necessary.
Results
• We controlled the patients after 1 day , in 14 day they had a clinical examination on the neurosurgery department , after 1month , in 3 and 6 month they receive a MRI control of the affected region and they were invited to do the questionnaires after 1 year . Due to the fact that this was not a randomized study it was very difficult to activate the patients participations. The results of vertebroplasty was sometimes miraculous so that the patients disappeared without any follow-up . We started with 534 patient and after 1 year there were only 124 left for the questionnaires.(76%) The disappearance of the patient was mostly at 1-6 months where the clinical response on the cementing were maximized. This differ totally in the conservative group who were recruited from the orthopaedic department. Here we lost the patient after 6 months (128 → 89)(24%).
151
• The first questionnaire was the Visual analogue scale (VAS) on a (0) no pain to (10) worst pain ever. The VAS score was assessed on presentation, at 24 hours, 1 month, 6 ,12 months after therapy. With restriction of bed rest 3 hours after the vertebroplasty we revealed a pain reduction after 24 h 53 %( women) and 68% (Man). Typical was the maximum pain reduction between 14 days and 1 month. (75%).(P<0,001) With no significant changes recorded in the patients treated conservatively (P < 0,01 compared with Vertebroplasty)The changes diminished at 6 months but no differences between groups were evident at 12 months. Men showed a better improvement in pain scores at 24 h after vertebroplasty compared with women. The mean number of hospital bed days was 47% less than for patient treated conservatively. There was a dramatically improvement of 29% the first week after vertebroplasty.
This was significant different to conservative therapy who had no change at all the first week. (P < 0,001).
The improvement in conservative therapy started after 6 months (29%) to 1 year but stayed significant different to vertebroplasty (39% ) in 1 year.(P< 0,001). The SF-36 questionnaires demonstrated significant (p < 0,0001) functional improvement between the baseline and one-month scores. With the numbers available, there were no significant changes in any variable from one month to one year (p > 0,05).
The outcomes in vertebroplasty is significant early in comparison with conservative treatment.(P<0,001) • There were no significant differences in the risk of new fractures in the two groups. 
New Vertebral fractures:
25% new VCF ( 20,9% natural cause) 60% within 3 months after PV 48% symptomatic 56% adjacent vertebral body to treated VCF no correlation cement leakage intervertebral discal space, vertebral stiffness cause: progression underlying disease 1 .
Because mostly all patients needed hospitalisation after vertebral fracture we liked to treat the patient very early to reduce the total number of hospital beds.(47%)Very often (73%) the patient is an outpatient and the hospital stay is reduce to less than one day in comparison of the conservative treated patient (8-14 days).
Complications
• All adverse events were reported and treated if necessary .We saw a cement leakage in 34% of the patients but they were only in 0, 1 % clinical evident. Bone cement leakage was assessed by intraoperative fluoroscopy and postoperative CT and included vertebrae with any noticeable cement outside vertebral borders. There were no major complications such as pulmonary emboli, pedicular fractures or neurological deficits due to cement leakage and canal narrowing. We had 5 patient with local neuritis and 3 patients with increasing of the pain after cement injection. All symptoms disappeared in less than 1 week after a treatment with NSAID analgesics.
Discussion
• This large review resulted in improvements in quality of live and disability measures and reduction of back pain in patients with acute painful vertebral fractures. Vertebroplasty is an effective treatment for patients with intractable pain due to osteoporotic vertebral compression fractures. Improvement in pain scores and functional capabilities that were found at one month were maintained at one year. However, differences in improvement between vertebroplasty and conservative therapy diminished by 1 year. This study has several limitations. Because the intervention was not blinded, we cannot rule out the possibility that knowledge of the treatment assignment might have determined patient responses to questions or radiologist assessments of new vertebral fractures, which could contributed to the greater improvements seen in the vertebroplasty group. Randomized and blinded trials are needed in order to reduce the risk of overestimating the treatment effect. High-quality observational studies with extended follow-up, national quality registers, are essential to determine the long-term effects and risks (figure 2). • Since 2003 we started a multicentre double blind randomized study VERTOS II with 200 patients. (Inclusion criteria; vertebral compression fracture (Type A.1-3.1) local back pain, 6 weeks or less. bone Oedema (MRI). Osteopenia or osteoporosis (T score = -2, 5). Age ≥ 50 years • The result will be presented at the meeting. Since the results are to date of this presentation not ready, I am not able to give any further information about this very interesting and long term study. • These findings will help to inform decisions about the use of vertebroplasty as an early treatment option for patient population.
